Suche klinische Studie
Weitere Suchoptionen
10 Ergebnis(se)
Rekrutierende Studie = 
; Fortlaufende Studie = 
; Abgeschlossene Studie = 
; Förderung durch ein IRDiRC-Mitglied = 
; ERN-Mitglied = 
Nationale klinische Studie(n)
OSTERREICH
WIEN
WIEN
HCQ4Surfdefect: Hydroxychloroquine (HCQ) in pediatric ILD (interstitial lung disease) - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Pädiatrische Pulmologie, Allergologie und Endokrinologie
DEUTSCHLAND
Hessen
FRANKFURT AM MAIN
Phase I/II G1XCGD.01 Sudie: Nicht randomisierte, multizentrische, offene Phase I/II-Gentherapiestudie mit g1xcgd (Lentiviral Vector Transduced cd34+ Cells) zur Behandlung der X-chromosomalen chronischen Granulomatose
Universitätsklinikum Frankfurt
Medizinische Klinik II - Hämatologie, Onkologie, Hämostaseologie, Rheumatologie, Infektiologie
FRANKREICH
ILE-DE-FRANCE
PARIS
A Phase I/II, Non Randomized, Monocentric Open-label Study of Autologous CD34+ Cells Transduced With the G1XCGD Lentiviral Vector in Patients With X-Linked Chronic Granulomatous Disease
Hôpital Necker-Enfants Malades
Service d'Immuno-hématologie pédiatrique
JAPAN
JAPAN
ADDRESS : NOT PROVIDED - JP
Double-blind placebo-controlled clinical trial of thalidomide for chronic granulomatous disease-associated colitis
Institution: Information not provided - JP
VEREINIGTES KONIGREICH
Greater London
LONDON
A phase I/II, non randomized, multicenter, open-label study of G1XCGD (lentiviral vector transduced CD34+ cells) in patients with X-Linked Chronic Granulomatous Disease - UK
Great Ormond Street Hospital
Molecular and Cellular Immunology Unit
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
GLYCO-1B: Evaluation of the Safety and Efficacy of Empagliflozin Administration as a Treatment for Neutropenia in Patients With Glycogenosis Type 1b and G6PC3 Deficiency
Cliniques universitaires Saint-Luc - UCLouvain
Cliniques Universitaires Saint-Luc
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients With WHIM Syndrome With Open-Label Extension - AT
Institution: Information not provided - AT
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients With WHIM Syndrome With Open-Label Extension -ES
Institution: Information not provided - ES
SPANIEN
Madrid
MADRID
Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I):A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of the Infusion of Autologous Hematopoietic Stem Cells Transduced with a Lentiviral Vector Encoding the ITGB2 Gene -ES
Hospital Infantil Universitario Niño Jesús
Multinationale klinische Studie(n)
FRANKREICH
ILE-DE-FRANCE
EVRY